Literature DB >> 15543611

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.

Juana Maria Garcia Pedrero1, Dario Garcia Carracedo, Cristina Muñoz Pinto, Agustín Herrero Zapatero, Juan Pablo Rodrigo, Carlos Suarez Nieto, Maria Victoria Gonzalez.   

Abstract

We investigated the status of the PI 3-kinase/AKT/PTEN signaling pathway in a series of 117 head and neck squamous cell carcinomas (HNSCC) in a search for molecular alterations in genes/proteins with potential prognostic value. For this purpose, PIK3CA and AKT2 gene amplification was assessed by multiplex and Quantitative Real-Time PCR. Protein expression of AKT, p-AKT, p110alpha and PTEN was determined by Western blot. PTEN allelic loss was evaluated by microsatellite analysis. PTEN-exon 5 was screened for point mutations by PCR-SSCP. Homozygous deletions were determined by multiplex PCR. PIK3CA gene was amplified in 43/117 (37%) fresh tumor samples, a frequency that did not differ from that found in archival premalignant tissues: 15/38 (39%); 12/40 (30%) fresh tumors harbored AKT2 gene amplification. AKT was found activated in 6/36 (17%) fresh tumor samples, when compared to their normal tissue counterparts. Of these 6 cases, 1 showed p110alpha overexpression and 5 displayed PTEN protein downregulation. Neither allelic loss (found in 11/77 informative cases) nor point mutations or homozygous deletions accounted for the reduced PTEN protein expression observed in our tumor series. The histologically normal mucosa of 4 patients displayed some of the molecular alterations analyzed. Dysregulation of the PI 3-K/AKT/PTEN pathway might contribute to early HNSCC tumorigenesis and might constitute a potential clinical target. Overall, 17/36 (47%) cases showed at least 1 of the molecular alterations studied here, which makes the PI 3-kinase-initiated signaling pathway one of the most frequently altered in HNSCC. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15543611     DOI: 10.1002/ijc.20711

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  92 in total

1.  Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.

Authors:  Luc G T Morris; Barry S Taylor; Trever G Bivona; Yongxing Gong; Stephanie Eng; Cameron W Brennan; Andrew Kaufman; Edward R Kastenhuber; Victoria E Banuchi; Bhuvanesh Singh; Adriana Heguy; Agnes Viale; Ingo K Mellinghoff; Jason Huse; Ian Ganly; Timothy A Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Authors:  Mitchell J Frederick; Amy J VanMeter; Mayur A Gadhikar; Ying C Henderson; Hui Yao; Curtis C Pickering; Michelle D Williams; Adel K El-Naggar; Vlad Sandulache; Emily Tarco; Jeffrey N Myers; Gary L Clayman; Lance A Liotta; Emanuel F Petricoin; Valerie S Calvert; Valentina Fodale; Jing Wang; Randal S Weber
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

4.  Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma.

Authors:  Geoffrey Childs; Melissa Fazzari; Gloria Kung; Nicole Kawachi; Margaret Brandwein-Gensler; Michael McLemore; Quan Chen; Robert D Burk; Richard V Smith; Michael B Prystowsky; Thomas J Belbin; Nicolas F Schlecht
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

5.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; M Fernanda Lara; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Kaoru Kiguchi; Agueda Buitrago; Clotilde Costa; Cristina Saiz; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; Marina Garín; Teresa Grande; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.

Authors:  Wanglong Qiu; Guo-Xia Tong; Spiros Manolidis; Lanny G Close; Adel M Assaad; Gloria H Su
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

Review 7.  Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Authors:  Qun Liu; Kristen M Turner; W K Alfred Yung; Kexin Chen; Wei Zhang
Journal:  Neuro Oncol       Date:  2014-05-07       Impact factor: 12.300

8.  Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.

Authors:  Hua-Chuan Zheng; Koichi Tsuneyama; Hiroyuki Takahashi; Shigeharu Miwa; Toshiro Sugiyama; Boryana Konstantinova Popivanova; Chifumi Fujii; Kazuhiro Nomoto; Naofumi Mukaida; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-18       Impact factor: 4.553

9.  Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Agueda Buitrago; Clotilde Costa; Cristina Saiz; José M Ariza; Marta Dueñas; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; John Digiovanni; Jesús M Paramio
Journal:  In Vivo       Date:  2009 Sep-Oct       Impact factor: 2.155

10.  MicroRNA expression in head and neck cancer associates with alcohol consumption and survival.

Authors:  Michele Avissar; Michael D McClean; Karl T Kelsey; Carmen J Marsit
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.